Driven by high-level corporate designations, more than 20 leading international pharmaceutical powerhouses—including multiple global Top-5 mega-pharma corporations by market capitalization—have aggressively advanced formal credentials to lock in exclusive, “closed-door” one-on-one bilateral negotiation windows with Sunhawk Vision during the convention. These strategic, high-density summits will enter into substance-level evaluations regarding multi-regional exclusive licensing and premium equity partnerships for our pioneering, First-in-Class microRNA nucleic acid ophthalmic platform.
This overwhelming interest underscores the international market’s high recognition of our company’s technical moat. While steadfastly safeguarding the core interests of the company and its shareholders, Sunhawk Vision will carefully evaluate the commercial Term Sheets proposed by these multinational corporations (MNCs) to secure the most strategically valuable global partnership for the SHJ002 platform pipeline.